Human Toxicology, cilt.5, sa.5, ss.333-335, 1986 (SCI-Expanded)
1. N-acetyltransferase phenotype has been determined in 109 control subjects and in 23 patients with bladder cancer. 2. Sixty-two per cent of control, and 39% of patients with bladder cancer were phenotypically slow acetylators. This difference was not significant. 3. N-acetyltransferase phenotype is unlikely to be a major determinant in the development of bladder cancer in the Turkish population.